


Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

October 2026

The logo for PHARMAC (Te Pātaka Whaioranga) is centered within a white circle. The background of the entire page is a solid grey color. Below the circle, there are stylized, concentric, wavy lines in white and grey, resembling a stylized 'S' or a series of overlapping waves. The text 'PHARMAC' is in a large, bold, sans-serif font, and 'TE PĀTAKA WHAIORANGA' is in a smaller, bold, sans-serif font below it.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 October 2026 3

Section H changes to Part II 6

Index 14

Summary of decisions

EFFECTIVE 1 OCTOBER 2026

- Aflibercept (Eylea) inj 40 mg per ml, 0.1 ml vial – new Pharmacode listing
- Amino acid formula (without phenylalanine) (Phlexy 10) tab 8.33 mg – to be delisted 1 December 2026
- Amino acid formula (without phenylalanine) (Easiphen Liquid) liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton – to be delisted 1 March 2027
- Aripiprazole (Aripiprazole Sandoz) tab 5 mg, 10 mg, 15 mg, 20 mg and 30 mg – price decrease and addition of PSS
- Betahistine dihydrochloride (Serc) tab 16 mg – new Pharmacode listing
- Candesartan cilexetil (Candesarten Viatris) tab 32 mg – new pack size listing
- Cefotaxime (DBL Cefotaxime) inj 1 g vial – price increase and addition of PSS
- Cyclopentolate hydrochloride (Minims Cyclopentolate) eye drops 1%, single dose, 20 dose – new listing and addition of PSS
- Cyclopentolate hydrochloride (Cyclogyl) eye drops 1%, 15 ml – to be delisted 1 March 2027
- Dapsone (Dapsomed) tab 50 mg and 100 mg – new listing, brand change and addition of PSS
- Dapsone tab 25 mg (Dapsone and Dapsone (Rising)) and tab 100 mg (Dapsone) – to be delisted 1 March 2027
- Diazepam (Arrow-Diazepam) tab 2 mg and 5 mg – price increase and addition of PSS
- Dimethicone (EVARA Dimethicone 10% Cream) crm 10% pump bottle, 480 g – new listing and addition of PSS
- Dimethicone (healthE Dimethicone 10%) crm 10% pump bottle, 460 g – to be delisted 1 March 2027
- Disopyramide (Rythmodan (Cheplapharm)) cap 100 mg – new listing and amended chemical name
- Entecavir (Entecavir Sandoz) tab 0.5 mg – new listing and addition of PSS
- Entecavir (Entecavir (Rex)) tab 0.5 mg – to be delisted 1 March 2027
- Exemestane (Pfizer Exemestane) tab 25 mg – price increase and addition of PSS
- Ezetimibe with simvastatin tab 10 mg with simvastatin 10 mg (Vytorin), tab 10 mg with simvastatin 20 mg (Ezetimibe Simvastatin Viatris) and tab 10 mg with simvastatin 40 mg (Ascend) – new listing
- Fluconazole (APO Health Fluconazole One) cap 150 mg – new listing
- Glycerol trioleate (GTO Oil) liquid, bottle – delisted 1 October 2026

Summary of decisions – effective 1 October 2026 (continued)

- Glycomacropeptide and amino acid contains some phenylalanine (PKU GMPro LQ) liquid (neutral), 10 g protein, 8.5 g carbohydrate per 250 ml carton – to be delisted 1 December 2026
 - Icatibant (Icatibant Lupin) inj 10 mg per ml, 3 ml prefilled syringe – amended restriction criteria
 - Influenza vaccine (Influvac Tetra (2026 formulation)) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – amended restriction criteria
 - Latanoprost with timolol (Arrow – Lattim) eye drops 0.005% with timolol 0.5%, 2.5 ml – price increase and addition of PSS
 - Loratadine (Haylor Syrup) oral liq 1 mg per ml – price increase
 - Mercaptopurine (Mercaptopurine (Sterimax)) tab 50 mg – new listing
 - Methylphenidate hydrochloride (Rubifen LA) cap modified-release 10 mg, 20 mg, 30 mg, 40 mg and 60 mg – new listing
 - Methylphenidate hydrochloride – amended restriction criteria
 - Tab extended-release 18 mg (Concerta and Methylphenidate ER – Teva)
 - Tab extended-release 27 mg (Concerta and Methylphenidate ER – Teva)
 - Tab extended-release 36 mg (Concerta and Methylphenidate ER – Teva)
 - Tab extended-release 54 mg (Concerta and Methylphenidate ER – Teva)
 - Tab immediate-release 5 mg (Rubifen)
 - Tab immediate-release 10 mg (Ritalin and Rubifen)
 - Tab modified-release 18 mg (Methylphenidate Sandoz XR)
 - Tab immediate-release 20 mg (Rubifen)
 - Tab sustained-release 20 mg (Rubifen SR)
 - Tab modified-release 27 mg (Methylphenidate Sandoz XR)
 - Tab modified-release 36 mg (Methylphenidate Sandoz XR)
 - Tab modified-release 54 mg (Methylphenidate Sandoz XR)
 - Cap modified-release 10 mg (Ritalin LA and Rubifen LA)
 - Cap modified-release 20 mg (Ritalin LA and Rubifen LA)
 - Cap modified-release 30 mg (Ritalin LA and Rubifen LA)
 - Cap modified-release 40 mg (Ritalin LA and Rubifen LA)
 - Cap modified-release 60 mg (Ritalin LA and Rubifen LA)
 - Nifedipine (Nifedipine Extended Release (Viatris)) tab long-acting 60 mg – new listing
 - Olanzapine (Zyprexa Zydis) tab orodispersible 5 mg – new listing
 - Omeprazole (Omeprazole Teva) cap 10 mg, 20 mg and 40 mg – price increase and addition of PSS
-

Summary of decisions – effective 1 October 2026 (continued)

- Omeprazole cap 10 mg (Omeprazole actavis 10), cap 20 mg (Omeprazole actavis 20) and cap 40 mg (Omeprazole actavis 40) – to be delisted 1 March 2027
- Oxycodone hydrochloride (Oxycodone Amneal) tab immediate-release 5 mg, 10 mg and 20 mg – price increase
- Pegaspargase (Oncaspar) inj 750 iu per ml, 5 ml vial – amended brand name
- Pegylated interferon alfa-2a (Pegasys S29 (ANZ)) inj 180 mcg prefilled syringe – new listing
- Pirfenidone (Pirfenidone Sandoz) tab 801 mg – new Pharmacode listing
- Povidone-iodine (Betadine) oint 10%, 65 g – new Pharmacode listing
- Prazosin (APO-Prazosin) tab 1 mg, 2 mg and 5 mg – price increase and amended brand name
- Progesterone (Utrogestan) cap 100 mg – to be delisted 1 February 2027
- Raltegravir potassium tab 400 mg (Isentress) and tab 600 mg (Isentress HD) – new Pharmacode listing
- Ribociclib (Kisqali) tab 200 mg – Pharmacodes 2701340 (21 pack), 2701359 (42 pack) and 2701367 (63 pack) to be delisted 1 March 2027
- Rifampicin (Rifadin) cap 150 mg and oral liq 100 mg per 5 ml, 60 ml – price increase and addition of PSS
- Rifampicin (Rifadin) cap 300 mg – addition of PSS
- Risperidone tab 1 mg (Risperidone Sandoz) and tab 3 mg (Relonchem) – new listing
- Rosuvastatin (Rosuvastatin Viatris, Rosuvastatin – Sandoz and Rosuvastatin Mylan) tab 5 mg, 10 mg, 20 mg and 40 mg – removal of restriction criteria
- Rosuvastatin (Rosuvastatin Viatris) tab 5 mg, 10 mg, 20 mg and 40 mg – price decrease and addition of PSS
- Rosuvastatin (Rosuvastatin – Sandoz and Rosuvastatin Mylan) tab 5 mg, 10 mg, 20 mg and 40 mg – to be delisted 1 March 2027
- Roxithromycin (Arrow-Roxithromycin) tab 150 mg and 300 mg – price increase and addition of PSS
- Sildenafil (Sildenafil (Crescent)) tab 25 mg – new listing
- Sumatriptan (Sumatriptan Viatris) tab 50 mg and 100 mg – new listing
- Thiotepa (Tepadina) inj 15 mg vial and 100 ml vial – price decrease and addition of PSS
- Tropicamide (Minims Tropicamide) eye drops 0.5%, single dose and eye drops 1%, single dose, 20 dose – new listing and addition of PSS
- Tropicamide (Mydriacyl) eye drops 0.5% and eye drops 1%, 15 ml – to be delisted 1 March 2027

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 October 2026

ALIMENTARY TRACT AND METABOLISM

8	OMEPRAZOLE (↑ price and addition of PSS)			
	Cap 10 mg – 5% DV Mar-27 to 2029	2.25	90	Omeprazole Teva
	Cap 20 mg – 5% DV Mar-27 to 2029	2.20	90	Omeprazole Teva
	Cap 40 mg – 5% DV Mar-27 to 2029	3.40	90	Omeprazole Teva
8	OMEPRAZOLE (delisting)			
	Cap 10 mg	2.06	90	Omeprazole actavis 10
	Cap 20 mg	2.02	90	Omeprazole actavis 20
	Cap 40 mg	3.18	90	Omeprazole actavis 40
	Note – Omeprazole actavis 10 cap 10 mg, omeprazole actavis 20 cap 20 mg and omeprazole actavis 40 cap 40 mg to be delisted from 1 March 2027.			

CARDIOVASCULAR SYSTEM

44	CANDESARTAN CILEXETIL (new pack size listing)			
	Tab 32 mg.....	1.75	30	Candesarten Viatris
45	PRAZOSIN (↑ price and amended brand name)			
	Tab 1 mg.....	6.17	100	APO-Prazosin Arrotex-Prazosin \$29
	Tab 2 mg.....	7.81	100	APO-Prazosin Arrotex-Prazosin \$29
	Tab 5 mg.....	13.05	100	APO-Prazosin Arrotex-Prazosin \$29
46	DISOPYRAMIDE PHOSPHATE (new listing and amended chemical name)			
	Cap 100 mg	66.55	100	Rythmodan (Cheplapharm)
48	NIFEDIPINE (new listing)			
	Tab long-acting 60 mg.....	7.40	14	Nifedipine Extended Release (Viatris)
51	ROSUVASTATIN (↓ price and addition of PSS)			
	Tab 5 mg – 5% DV Mar-27 to 2029	0.76	30	Rosuvastatin Viatris
	Tab 10 mg – 5% DV Mar-27 to 2029	0.98	30	Rosuvastatin Viatris
	Tab 20 mg – 5% DV Mar-27 to 2029	1.37	30	Rosuvastatin Viatris
	Tab 40 mg – 5% DV Mar-27 to 2029	2.24	30	Rosuvastatin Viatris

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2026 (continued)

51	ROSUVASTATIN (delisting)			
	Tab 5 mg.....	4.21	30	Rosuvastatin - Sandoz
		1.29		Rosuvastatin Mylan
	Tab 10 mg.....	4.21	30	Rosuvastatin - Sandoz
		1.69		Rosuvastatin Mylan
	Tab 20 mg.....	4.21	30	Rosuvastatin - Sandoz
		2.71		Rosuvastatin Mylan
	Tab 40 mg.....	4.55	30	Rosuvastatin - Sandoz
				Rosuvastatin Mylan

Note – Rosuvastatin – Sandoz and Rosuvastatin Mylan tab 5 mg, tab 10 mg, tab 20 mg and tab 40 mg to be delisted from 1 March 2027.

51	ROSUVASTATIN (removal of restriction criteria)			
	→ Tab 5 mg – 5% DV Mar-27 to 2029	4.21	30	Rosuvastatin - Sandoz
		1.29		Rosuvastatin Mylan
		0.76		Rosuvastatin Viatris
	→ Tab 10 mg – 5% DV Mar-27 to 2029	4.21	30	Rosuvastatin - Sandoz
		1.69		Rosuvastatin Mylan
		0.98		Rosuvastatin Viatris
	→ Tab 20 mg – 5% DV Mar-27 to 2029	4.21	30	Rosuvastatin - Sandoz
		2.71		Rosuvastatin Mylan
		1.37		Rosuvastatin Viatris
	→ Tab 40 mg – 5% DV Mar-27 to 2029	4.55	30	Rosuvastatin - Sandoz
				Rosuvastatin Mylan
		2.24		Rosuvastatin Viatris

Restricted

Initiation – cardiovascular disease risk

Either:

1– Both:

1.1– Patient is considered to be at risk of cardiovascular disease; and

1.2– Patient is Māori or any Pacific ethnicity; or

2– Both:

2.1– Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and

2.2– LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation – familial hypercholesterolemia

Both:

1– Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and

2– LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation – established cardiovascular disease

Both:

1– Any of the following:

1.1– Patient has proven coronary artery disease (CAD); or

1.2– Patient has proven peripheral artery disease (PAD); or

1.3– Patient has experienced an ischaemic stroke; and

2– LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation – recurrent major cardiovascular events

Both:

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2026 (continued)

continued...

- † Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
 2– LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

52	EZETIMIBE WITH SIMVASTATIN (new listing)			
	Tab 10 mg with simvastatin 10 mg	11.86	30	Vytorin
	Tab 10 mg with simvastatin 20 mg	41.83	100	Ezetimibe Simvastatin Viartis
	Tab 10 mg with simvastatin 40 mg	11.55	30	Ascend
60	SILDENAFIL (new listing)			
	→ Tab 25 mg.....	0.72	4	Sildenafil (Crescent)

DERMATOLOGICALS

67	DIMETHICONE (brand change and addition of PSS)			
	Crm 10% pump bottle – 5% DV Mar-27 to 2029	3.60	480 g	EVARA Dimethicone 10% Cream
	Note – healthE Dimethicone 10% crm 10% pump bottle, 460 g to be delisted from 1 March 2027.			

GENITO-URINARY SYSTEM

75	PROGESTERONE (delisting)			
	Cap 100 mg	14.85	30	Utrogestan
	Note – Utrogestan cap 100 mg to be delisted from 1 February 2027. This delist applies to Pharmacode 2730340.			

INFECTIONS

89	CEFOTAXIME († price and addition of PSS)			
	Inj 1 g vial – 5% DV Mar-27 to 2029	99.52	10	DBL Cefotaxime
92	ROXITHROMYCIN († price and addition of PSS)			
	Tab 150 mg – 5% DV Mar-27 to 2029	18.10	50	Arrow-Roxithromycin
	Tab 300 mg – 5% DV Mar-27 to 2029	35.69	50	Arrow-Roxithromycin
97	FLUCONAZOLE (new listing)			
	→ Cap 150 mg	0.45	1	APO Health Fluconazole One
100	DAPSONE (new listing, brand change and addition of PSS)			
	→ Tab 50 mg – 5% DV Mar-27 to 2029	188.28	100	Dapsomed
	→ Tab 100 mg – 5% DV Mar-27 to 2029	212.98	100	Dapsomed
	Note – Dapsone and Dapsone (Rising) tab 25 mg and Dapsone tab 100 mg to be delisted from 1 March 2027.			
101	RIFAMPICIN († price and addition of PSS)			
	→ Cap 150 mg – 5% DV Mar-27 to 2029	68.40	100	Rifadin
	→ Oral liq 100 mg per 5 ml – 5% DV Mar-27 to 2029	14.10	60 ml	Rifadin
101	RIFAMPICIN (addition of PSS)			
	→ Cap 300 mg– 5% DV Mar-27 to 2029	122.06	100	Rifadin

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2026 (continued)

106	RALTEGRAVIR POTASSIUM (new listing)			
	→ Tab 400 mg.....	1,090.00	60	Isentress
	→ Tab 600 mg.....	1,090.00	60	Isentress HD
	Note – these are new Pharmacode listings, 2736004 and 2736012, respectively.			
106	ENTECAVIR (brand change and addition of PSS)			
	Tab 0.5 mg – 5% DV Mar-27 to 2029	6.73	30	Entecavir Sandoz
	Note – Entecavir (Rex) tab 0.5 mg to be delisted from 1 March 2027.			
111	PEGYLATED INTERFERON ALFA-2A (new listing)			
	→ Inj 180 mcg prefilled syringe.....	1,074.79	4	Pegasys S29 (ANZ)

NERVOUS SYSTEM

127	OXYCODONE HYDROCHLORIDE (↑ price)			
	Tab immediate-release 5 mg.....	16.01	100	Oxycodone Amneal
	Tab immediate-release 10 mg.....	21.35	100	Oxycodone Amneal
	Tab immediate-release 20 mg.....	32.02	100	Oxycodone Amneal
132	SUMATRIPTAN (new listing)			
	Tab 50 mg.....	1.44	9	Sumatriptan Viatris
	Tab 100 mg.....	2.27	9	Sumatriptan Viatris
133	BETAHISTINE DIHYDROCHLORIDE (new listing)			
	Tab 16 mg – 5% DV Feb-27 to 2029	6.55	100	Serc
	Note – this is a new Pharmacode listing, 2712393.			
134	ARIPIPRAZOLE (↓ price and addition of PSS)			
	Tab 5 mg – 5% DV Mar-27 to 2029	6.90	30	Aripiprazole Sandoz
	Tab 10 mg – 5% DV Mar-27 to 2029	6.90	30	Aripiprazole Sandoz
	Tab 15 mg – 5% DV Mar-27 to 2029	7.41	30	Aripiprazole Sandoz
	Tab 20 mg – 5% DV Mar-27 to 2029	7.41	30	Aripiprazole Sandoz
	Tab 30 mg – 5% DV Mar-27 to 2029	7.41	30	Aripiprazole Sandoz
135	OLANZAPINE (new listing)			
	Tab orodispersible 5 mg	2.42	28	Zyprexa Zydys
135	RISPERIDONE (new listing)			
	Tab 1 mg.....	4.50	60	Risperidone Sandoz
	Tab 3 mg.....	12.45	60	Relonchem
138	DIAZEPAM (↑ price and addition of PSS)			
	Tab 2 mg – 5% DV Mar-27 to 2029	106.40	500	Arrow-Diazepam
	Tab 5 mg – 5% DV Mar-27 to 2029	128.80	500	Arrow-Diazepam
145	METHYLPHENIDATE HYDROCHLORIDE (new listing)			
	→ Cap modified-release 10 mg	14.82	30	Rubifen LA
	→ Cap modified-release 20 mg	19.38	30	Rubifen LA
	→ Cap modified-release 30 mg	24.24	30	Rubifen LA
	→ Cap modified-release 40 mg	29.07	30	Rubifen LA
	→ Cap modified-release 60 mg	34.68	30	Rubifen LA

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2026 (continued)

145	METHYLPHENIDATE HYDROCHLORIDE (amended restriction criteria – affected criteria shown only)			
	→ Tab extended-release 18 mg	58.96	30	Concerta
		15.25		Methylphenidate ER - Teva
	→ Tab extended-release 27 mg	65.44	30	Concerta
		16.25		Methylphenidate ER - Teva
	→ Tab extended-release 36 mg	71.93	30	Concerta
		21.25		Methylphenidate ER - Teva
	→ Tab extended-release 54 mg	86.24	30	Concerta
		24.25		Methylphenidate ER - Teva
	→ Tab immediate-release 5 mg	3.20	30	Rubifen
	→ Tab immediate-release 10 mg	4.00	30	Ritalin
		3.00		Rubifen
	→ Tab modified-release 18 mg	15.25	30	Methylphenidate Sandoz XR
	→ Tab immediate-release 20 mg	7.85	30	Rubifen
	→ Tab sustained-release 20 mg	10.95	30	Rubifen SR
	→ Tab modified-release 27 mg	16.25	30	Methylphenidate Sandoz XR
	→ Tab modified-release 36 mg	21.25	30	Methylphenidate Sandoz XR
	→ Tab modified-release 54 mg	24.25	30	Methylphenidate Sandoz XR
	→ Cap modified-release 10 mg	19.41	30	Ritalin LA
		14.82	30	Rubifen LA
	→ Cap modified-release 20 mg	27.72	30	Ritalin LA
		19.38	30	Rubifen LA
	→ Cap modified-release 30 mg	34.39	30	Ritalin LA
		24.24	30	Rubifen LA
	→ Cap modified-release 40 mg	38.67	30	Ritalin LA
		29.07	30	Rubifen LA
	→ Cap modified-release 60 mg	34.68	30	Rubifen LA
	Initiation – Narcolepsy* (extended-release only)			
	Neurologist or respiratory specialist			
	Patient suffers from narcolepsy.			
	Note: *narcolepsy is not a registered indication for Concerta, Ritalin LA, or Methylphenidate Sandoz XR or Rubifen LA.			

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

150	THIOTEPA (↓ price and addition of PSS)			
	Inj 15 mg vial – 5% DV Mar-27 to 2029	278.60	1	Tepadina
	Inj 100 mg vial – 5% DV Mar-27 to 2029	1,260.00	1	Tepadina
152	MERCAPTOPURINE (new listing)			
	Tab 50 mg	19.50	25	Mercaptopurine (Sterimax)
156	PEGASPARGASE (amended brand name)			
	→ Inj 750 iu per ml, 5 ml vial	3,973.25	1	Oncaspar LYO
169	RIBOCICLIB (delisting)			
	→ Tab 200 mg	1,883.00	21	Kisqali
		3,767.00	42	Kisqali
		5,650.00	63	Kisqali
	Note – Kisqali tab 200 mg to be delisted 1 March 2027. This delist apply to Pharmacodes 2701340 (21 pack), 2701359 (42 pack) and 2701367 (63 pack).			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2026 (continued)

174	EXEMESTANE (↑ price and addition of PSS) Tab 25 mg – 5% DV Mar-27 to 2029	18.97	30	Pfizer Exemestane
198	AFLIBERCEPT (new listing) → Inj 40 mg per ml, 0.1 ml vial	1,250.00	1	Eylea
	Note – this is a new Pharmacode listing, 2737876.			

RESPIRATORY SYSTEM AND ALLERGIES

262	ICATIBANT (amended restriction criteria) → Inj 10 mg per ml, 3 ml prefilled syringe – 5% DV Oct-26 to 2028	479.00	1	Icatibant Lupin
	Restricted Initiation Clinical immunologist or relevant specialist <i>Re-assessment required after 12 months</i> Both: 1 Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and 2 The patient has undergone product training and has agreed upon an action plan for self-administration. Continuation <i>Re-assessment required after 12 months</i> The treatment remains appropriate and the patient is benefiting from treatment.			
263	LORATADINE (↑ price) Oral liq 1 mg per ml	2.14	100 ml	Haylor Syrup
266	PIRFENIDONE (new Pharmacode listing) → Tab 801 mg – 5% DV Oct-26 to 2028	437.40	90	Pirfenidone Sandoz
	Note – this is a new Pharmacode listing, 2735652.			

SENSORY ORGANS

277	LATANOPROST WITH TIMOLOL (↑ price and addition of PSS) Eye drops 0.005% with timolol 0.5% – 5% DV Mar-27 to 2029	5.75	2.5 ml	Arrow - Lattim
278	CYCLOPENTOLATE HYDROCHLORIDE (pack size change and addition of PSS) Eye drops 1%, single dose – 5% DV Mar-27 to 2029	46.00	20 dose	Minims Cyclopentolate
	Note – Cyclogyl eye drops 1%, 15 ml to be delisted from 1 March 2027.			
278	TROPICAMIDE (pack size change and addition of PSS) Eye drops 0.5%, single dose – 5% DV Mar-27 to 2029	46.00	20 dose	Minims Tropicamide
	Eye drops 1%, single dose – 5% DV Mar-27 to 2029	46.00	20 dose	Minims Tropicamide
	Note – Mydracyl eye drops 0.5% and eye drops 1%, 15 ml to be delisted from 1 March 2027.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2026 (continued)

VARIOUS

282	POVIDONE-IODINE (new listing)			
	Oint 10%	7.40	65 g	Betadine
	Note – this is a new Pharmacode listing, 2730618			

SPECIAL FOODS

295	AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (delisting)			
	→ Tab 8.33 mg.....	99.00	75	Phlexy 10
	Note – Phlexy 10 tab 8.33 mg to be delisted from 1 December 2026.			
296	AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (delisting)			
	→ Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per			
	100 ml, 250 ml carton.....	540.00	18	Easiphen Liquid
	Note – Easiphen Liquid liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton to be delisted from 1 March 2027.			
296	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE (delisting)			
	→ Liquid (neutral), 10 g protein, 8.5 g carbohydrate per			
	250 ml carton	280.80	18	PKU GMPro LQ
	Note – PKU GMPro LQ liquid (neutral), 10 g protein, 8.5 g carbohydrate per 250 ml carton to be delisted from 1 December 2026.			
297	GLYCEROL TRIOLEATE (delisted)			
	→ Liquid, bottle.....	131.80	500 ml	GTO Oil
	Note – GTO Oil liquid, bottle delisted from 1 October 2026.			

VACCINES

316	INFLUENZA VACCINE (amended restriction criteria)			
	→ Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	120.00	10	Influvac Tetra (2026 formulation)
	Restricted			
	Initiation – All children under 59 months			
	All children under 59 months inclusive.			
	Initiation – People over 65			
	The patient is 65 years of age or over.			
	Initiation – cardiovascular disease			
	Any of the following:			
	1 Ischaemic heart disease; or			
	2 Congestive heart failure; or			
	3 Rheumatic heart disease; or			
	4 Congenital heart disease; or			
	5 Cerebro-vascular disease.			
	Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.			
	Initiation – chronic respiratory disease			
	Either:			
	1 Asthma, if on a regular preventative therapy; or			
	2 Other chronic respiratory disease with impaired lung function.			
	Note: asthma not requiring regular preventative therapy is excluded from funding.			

continued...



(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 October 2026 (continued)

continued...

Initiation – Other conditions

Either:

1 Any of the following:

- 1.1 Diabetes; or
- 1.2 chronic renal disease; or
- 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
- 1.4 Autoimmune disease; or
- 1.5 Immune suppression or immune deficiency; or
- 1.6 HIV; or
- 1.7 Transplant recipient; or
- 1.8 Neuromuscular and CNS diseases/ disorders; or
- 1.9 Haemoglobinopathies; or
- 1.10 Is a child on long term aspirin; or
- 1.11 Has a cochlear implant; or
- 1.12 Errors of metabolism at risk of major metabolic decompensation; or
- 1.13 Pre and post splenectomy; or
- 1.14 Down syndrome; or
- 1.15 Is pregnant; or
- ~~1.16 Is a child 4 years of age or under (inclusive) who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or~~

2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a Public Hospital.

Initiation – Serious mental health conditions or addiction

Any of the following:

- 1 schizophrenia; or
- 2 major depressive disorder; or
- 3 bipolar disorder; or
- 4 schizoaffective disorder; or
- 5 person is currently accessing secondary or tertiary mental health and addiction services.

Index

Pharmaceuticals and brands

A

AFLIBERCEPT	11
AMINO ACID FORMULA (WITHOUT PHENYLALANINE)	12
APO Health Fluconazole One	8
APO-Prazosin	6
ARIPIRAZOLE	9
Aripiprazole Sandoz	9
Arrotex-Prazosin S29	6
Arrow-Diazepam	9
Arrow - Lattim	11
Arrow-Roxithromycin	8

B

Betadine	12
BETAHISTINE DIHYDROCHLORIDE	9

C

CANDESARTAN CILEXETIL	6
Candesarten Viatris	6
CEFOTAXIME	8
Concerta	10
CYCLOPENTOLATE HYDROCHLORIDE	11

D

Dapsomed	8
DAPSONE	8
DBL Cefotaxime	8
DIAZEPAM	9
DIMETHICONE	8
DISOPYRAMIDE	6
DISOPYRAMIDE PHOSPHATE	6

E

Easiphen Liquid	12
ENTECAVIR	9
Entecavir Sandoz	9
EVARA Dimethicone 10% Cream	8
EXEMESTANE	11
Eylea	11
Ezetimibe Simvastatin Viatris	8
EZETIMIBE WITH SIMVASTATIN	8

F

FLUCONAZOLE	8
-------------------	---

G

GLYCEROL TRIOLEATE	12
GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE	12
GTO Oil	12

H

Haylor Syrup	11
--------------------	----

I

ICATIBANT	11
Icatibant Lupin	11
INFLUENZA VACCINE	12
Influvac Tetra (2026 formulation)	12
Isentress	9
Isentress HD	9

K

Kisqali	10
---------------	----

L

LATANOPROST WITH TIMOLOL	11
LORATADINE	11

M

MERCAPTOPURINE	10
Mercaptopurine (Sterimax)	10
Methylphenidate ER - Teva	10
METHYLPHENIDATE HYDROCHLORIDE	9, 10
Methylphenidate Sandoz XR	10
Minims Cyclopentolate	11
Minims Tropicamide	11

N

NIFEDIPINE	6
Nifedipine Extended Release (Viatris)	6

O

OLANZAPINE	9
OMEPRAZOLE	6
Omeprazole actavis 10	6
Omeprazole actavis 20	6
Omeprazole actavis 40	6
Omeprazole Teva	6
Oncaspar	10
Oncaspar LYO	10
Oxycodone Amneal	9
OXYCODONE HYDROCHLORIDE	9

P

PEGASPARGASE	10
Pegasys S29 (ANZ)	9
PEGYLATED INTERFERON ALFA-2A	9
Pfizer Exemestane	11
Phlexy 10	12
PIRFENIDONE	11
Pirfenidone Sandoz	11
PKU GMPPro LQ	12
POVIDONE-IODINE	12
PRazosin	6
PROGESTERONE	8

R

RALTEGRAVIR POTASSIUM	9
Relonchem	9
RIBOCICLIB	10
Rifadin	8
RIFAMPICIN	8
RISPERIDONE	9
Risperidone Sandoz	9
Ritalin	10
Ritalin LA	10
ROSUVASTATIN	6, 7
Rosuvastatin Mylan	7
Rosuvastatin - Sandoz	7
Rosuvastatin Viatris	6, 7

Index

Pharmaceuticals and brands

ROXITHROMYCIN.....	8
Rubifen.....	10
Rubifen LA.....	9, 10
Rubifen SR.....	10
Rythmodan (Cheplapharm).....	6
S	
Serc.....	9
SILDENAFIL.....	8
Sildenafil (Crescent).....	8
SUMATRIPTAN.....	9
Sumatriptan Viatris.....	9

T	
Tepadina.....	10
THIOTEPA.....	10
TROPICAMIDE.....	11
U	
Utrogestan.....	8
V	
Vytorin.....	8
Z	
Zyprexa Zydis.....	9

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

